DEEP EXPERIENCE IN AMYLOID RESEARCH, THERAPEUTIC DEVELOPMENT & COMMERCIALIZATION
A COMPANY BRINGING NEW POSSIBILITIES
Attralus aims to transform the lives of patients with systemic amyloidosis with therapeutics that remove toxic amyloid.
We are advancing a pipeline of novel biologics designed for pan-amyloid removal – across all stages and types of systemic amyloidosis. In support of our paradigm-changing therapeutics, we are also developing the world’s first amyloidosis-specific diagnostic imaging agent which has the potential to set a new standard in the diagnosis of systemic amyloid and identify the many patients that remain undiagnosed.
Moving Fast with a Focus on Patients in Need
There are currently no treatments to remove amyloid in patients with systemic amyloidosis. Current treatments are applicable for some types of amyloidosis and reduce new amyloid formation which may slow disease progression. However, none of these existing therapies directly address the toxic amyloid already deposited in organs that leads to progressive organ failure and increased mortality.
Attralus is Advancing New Solutions
We are focused on addressing this unmet need for an amyloidosis therapy capable of broadly removing existing amyloid deposits, opening the door to improving organ function and reversing disease for patients with all types of systemic amyloidosis.
Our team of leading amyloidosis scientists and experts has researched and developed systemic amyloidosis therapeutics for more than 25 years.
Board of Directors
Knowledgeable business leaders and investors with demonstrated experience in building and scaling biotechnology companies.
Scientific Advisory Board
Attralus has assembled a world-class team of clinical and scientific advisors that includes recognized experts in amyloids, drug discovery, and clinical development.